| Literature DB >> 26028927 |
Satomi Koizumi1, Terumi Kamisawa1, Sawako Kuruma1, Taku Tabata1, Kazuro Chiba1, Susumu Iwasaki1, Go Kuwata1, Takashi Fujiwara1, Junko Fujiwara1, Takeo Arakawa1, Koichi Koizumi1, Kumiko Momma1.
Abstract
IgG4-related disease (IgG4-RD) is a potentially multiorgan disorder. In this study, clinical and serological features from 132 IgG4-RD patients were compared about organ correlations. Underlying pathologies comprised autoimmune pancreatitis (AIP) in 85 cases, IgG4-related sclerosing cholangitis (IgG4-SC) in 12, IgG4-related sialadenitis (IgG4-SIA) in 56, IgG4-related dacryoadenitis (IgG4-DAC) in 38, IgG4-related lymphadenopathy (IgG4-LYM) in 20, IgG4-related retroperitoneal fibrosis (IgG4-RF) in 19, IgG4-related kidney disease (IgG4-KD) in 6, IgG4-related pseudotumor (IgG4-PT) in 3. Sixty-five patients (49%) had multiple IgG4-RD (two affected organs in 36 patients, three in 19, four in 8, five in 1, and six in 1). Serum IgG4 levels were significantly higher with multiple lesions than with a single lesion (P<0.001). The proportion of association with other IgG4-RD was 42% in AIP, the lowest of all IgG4-RDs. Serum IgG4 level was lower in AIP than in other IgG4-RDs. Frequently associated IgG4-RDs were SIA (25%) and DAC (12%) for AIP; AIP (75%) for IgG4-SC; DAC (57%), AIP (38%) and LYM (27%) for IgG4-SIA; AIP (26%) and LYM (26%) for IgG4-DAC; SIA (75%), DAC (50%) and AIP (45%) for IgG4-LYM; SIA (58%), AIP (42%) and LYM (32%) for IgG4-RF; AIP (100%) and SIA (67%) for IgG4-KID; and DAC (67%) and SIA (67%) for IgG4-PT. Most associated IgG4-RD lesions were diagnosed simultaneously, but IgG4-SIA and IgG4-DAC were sometimes identified before other lesions. About half of IgG4-RD patients had multiple IgG4-RD lesions, and some associations were seen between specific organs.Entities:
Keywords: Cholangitis, Sclerosing; IgG4; Pancreatitis
Mesh:
Substances:
Year: 2015 PMID: 26028927 PMCID: PMC4444475 DOI: 10.3346/jkms.2015.30.6.743
Source DB: PubMed Journal: J Korean Med Sci ISSN: 1011-8934 Impact factor: 2.153
Diagnosis of IgG4-related disease
| Diseases | No. of cases | Definite (%) | Probable (%) | Possible (%) |
|---|---|---|---|---|
| IgG4-RD | 132 | 111 (84) | 3 (2) | 18 (14) |
| AIP | 85 | 72 (85) | 3 (3) | 10 (12) |
| SC | 12 | 11 (92) | 0 | 1 (8) |
| DAC | 38 | 36 (95) | 0 | 2 (5) |
| SIA | 56 | 50 (89) | 0 | 6 (11) |
| LYM | 20 | 19 (95) | 0 | 1 (5) |
| RF | 19 | 17 (89) | 0 | 2 (11) |
| KD | 6 | 6 (100) | 0 | 0 |
| PT | 3 | 3 (100) | 0 | 0 |
AIP, autoimmune pancreatitis; SC, IgG4-related sclerosing cholangitis; DAC, IgG4-related dacryoadenitis; SIA, IgG4-related sialadenitis; LYM, IgG4-related lymphadenopathy; RF, IgG4-related retroperitoneal fibrosis; KD, IgG4-related kidney disease; PT, IgG4-related pseudotumor.
Comparison of clinical and serological features between single and multiple lesions
| Parameters | Single lesion | Double lesions | Triple lesions | Four or more lesions |
|---|---|---|---|---|
| No. | 67 | 36 | 19 | 10 |
| Male:Female | 46:21 | 22:14 | 11:8 | 8:2 |
| IgG4 (mg/dL) | 307.4 | 655.2* | 930.9* | 976.6* |
| IgG (mg/dL) | 2,003.6 | 2,190.9 | 2,432.8 | 2,644.2 |
*P<0.001 compared to single lesion. Serum IgG4 levels were significantly higher in patients with multiple lesions (783.2 mg/dL) than in those with a single lesion (P<0.01).
Clinical feature of each organ for IgG4-related disease
| Features | IgG4-RD | AIP | SC | DAC | SIA | LYM | RF | KID | PT |
|---|---|---|---|---|---|---|---|---|---|
| No. association | 132 | 85 | 12 | 38 | 56 | 20 | 19 | 6 | 3 |
| Single lesion | 67 | 49 | 3 | 3 | 7 | 2 | 2 | 0 | 1 |
| Multiple lesion | 65 | 36 | 9 | 35 | 49 | 18 | 17 | 6 | 2 |
| Double lesions | 36 | 17 | 6 | 16 | 24 | 2 | 6 | 1 | 0 |
| Triple lesions | 19 | 13 | 2 | 10 | 15 | 9 | 6 | 2 | 0 |
| Four lesions | 8 | 4 | 1 | 8 | 8 | 5 | 3 | 2 | 1 |
| Five lesions | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 |
| Six lesions | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
| Rate (%) | 0 | 42 | 75 | 92 | 88 | 90 | 89 | 100 | 67 |
| Serum levels | |||||||||
| IgG4 (mg/dL) | 548.3 | 491.0 | 568.0 | 724.8 | 821.3 | 979.0 | 769.1 | 524.5 | 600.0 |
| IgG (mg/dL) | 2,094.2 | 2,082.0 | 2,402.0 | 2,107.8 | 2,432.8 | 2,687.4 | 2,526.8 | 1,838.3 | 1,967.0 |
| Treatment | |||||||||
| Steroid | 82 | 60 (71%) | 10 (83%) | 21 (55%) | 30 (54%) | 7 (35%) | 13 (68%) | 5 (83%) | 1 (33%) |
| Observation | 36 | 15 | 1 | 17 | 22 | 12 | 6 | 1 | 0 |
| Operation | 14 | 10 | 1 | 0 | 4 | 1 | 0 | 0 | 2 |
AIP, autoimmune pancreatitis; SC, IgG4-related sclerosing cholangitis; DAC, IgG4-related dacryoadenitis; SIA, IgG4-related sialadenitis; LYM, IgG4-related lymphadenopathy; RF, IgG4-related retroperitoneal fibrosis; KD, IgG4-related kidney disease; PT, IgG4-related pseudotumor.
Fig. 1Venn diagram showing correlation between autoimmune pancreatitis and associated other IgG4-related diseases.
Fig. 2Venn diagram showing correlation between IgG4-related sialadenitis and associated other IgG4-related diseases.
Fig. 3Venn diagram showing correlation between IgG4-related dacryoadenitis and associated other IgG4-related diseases.
Synchronous and metachronous association of other IgG4-related diseases
| Associated IgG4-RD | AIP (n=85) | SC (n=12) | DAC (n=38) | SIA (n=56) | LYM (n=20) | RF (n=19) | KID (n=6) | PT (n=3) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n (%) | B | S | A | n (%) | B | S | A | n (%) | B | S | A | n (%) | B | S | A | n (%) | B | S | A | n (%) | B | S | A | n (%) | B | S | A | n (%) | B | S | A | |
| AIP | 9 (75) | 0 | 9 | 0 | 10 (26) | 1 | 5 | 4 | 21 (38) | 2 | 14 | 5 | 9 (45) | 0 | 7 | 2 | 8 (42) | 1 | 6 | 1 | 6 (100) | 0 | 6 | 0 | 1 (33) | 0 | 1 | 0 | ||||
| SC | 9 (11) | 0 | 9 | 0 | 1 (3) | 0 | 1 | 0 | 2 (4) | 0 | 1 | 1 | 1 (5) | 0 | 1 | 0 | 0 (0) | 0 | 0 | 0 | 0 (0) | 0 | 0 | 0 | 0 (0) | 0 | 0 | 0 | ||||
| DAC | 10 (12) | 4 | 5 | 1 | 1 (8) | 0 | 1 | 0 | 32 (57) | 3 | 27 | 2 | 10 (50) | 0 | 9 | 1 | 8 (43) | 3 | 3 | 0 | 2 (33) | 0 | 2 | 0 | 1 (33) | 1 | 0 | 0 | ||||
| SIA | 21 (25) | 5 | 14 | 2 | 2 (17) | 0 | 1 | 0 | 32 (84) | 2 | 27 | 3 | 15 (75) | 2 | 12 | 1 | 11 (58) | 3 | 8 | 0 | 4 (67) | 0 | 4 | 0 | 2 (67) | 0 | 2 | 0 | ||||
| LYM | 9 (10) | 2 | 7 | 0 | 1 (8) | 0 | 1 | 0 | 10 (26) | 1 | 9 | 0 | 15 (27) | 1 | 12 | 2 | 6 (32) | 1 | 5 | 0 | 1 (17) | 0 | 1 | 0 | 2 (67) | 0 | 2 | 0 | ||||
| RF | 8 (9) | 1 | 6 | 1 | 0 (0) | 0 | 0 | 0 | 8 (21) | 0 | 5 | 3 | 11 (20) | 0 | 8 | 3 | 6 (3) | 0 | 5 | 1 | 2 (33) | 0 | 2 | 0 | 1 (33) | 0 | 1 | 0 | ||||
| KID | 6 (7) | 0 | 6 | 0 | 0 (0) | 0 | 0 | 0 | 2 (5) | 0 | 2 | 0 | 4 (7) | 0 | 4 | 0 | 1 (5) | 0 | 1 | 0 | 2 (11) | 0 | 2 | 0 | 1 (33) | 0 | 1 | 0 | ||||
| PT | 1 (1) | 0 | 1 | 0 | 0 (0) | 0 | 0 | 0 | 1 (3) | 0 | 0 | 1 | 2 (4) | 0 | 2 | 0 | 2 (10) | 0 | 2 | 0 | 1 (5) | 0 | 1 | 0 | 1 (17) | 0 | 1 | 0 | ||||
B, before; S, synchronous; A, after; AIP, autoimmune pancreatitis; SC, IgG4-related sclerosing cholangitis; DAC, IgG4-related dacryoadenitis; SIA, IgG4-related sialadenitis; LYM, IgG4-related lymphadenopathy; RF, IgG4-related retroperitoneal fibrosis; KD, IgG4-related kidney disease; PT, IgG4-related pseudotumor.